DSIP
Also known as: Delta Sleep-Inducing Peptide
Last updated: 1/23/2026 Last reviewed: 1/23/2026
At a Glance
DSIP (delta sleep-inducing peptide) is a peptide discussed in older sleep literature. Modern reviews emphasize that DSIP remains controversial and that key questions around endogenous DSIP, reproducibility, and mechanism are unresolved. [PMID: 16539679]
⚠️ Research Status: DSIP is not an approved medication. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
Mechanism claims vary across the literature and remain debated; treat strong mechanistic statements as hypothesis until supported by reproducible primary data. [PMID: 16539679]
Evidence Summary
Low Confidence Review 3-10 YearsReview-level synthesis highlights unresolved biology and inconsistent evidence base. [PMID: 16539679]
Safety & Unknowns
- Robust, modern clinical safety data are not established in the accessible literature.
- Interactions with other CNS-active agents are not well characterized.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |